![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Instituto de Olhos de Goiania |
---|---|
Information provided by: | Instituto de Olhos de Goiania |
ClinicalTrials.gov Identifier: | NCT00557232 |
Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers.
Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.
Condition | Intervention | Phase |
---|---|---|
Glaucoma Rubeosis Iridis |
Drug: bevacizumab |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Three of the following clinical tests must be present to demonstrate ischemic CRVO:
Exclusion Criteria:
Study ID Numbers: | JN-01-2007-ARVO |
Study First Received: | November 8, 2007 |
Last Updated: | November 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00557232 History of Changes |
Health Authority: | Brazil: National Health Surveillance Agency |
bevacizumab rubeosis iridis glaucoma |
Glaucoma Eye Diseases Retinal Vein Occlusion Bevacizumab Ischemia |
Angiogenesis Inhibitors Glaucoma, Neovascular Hypertension Ocular Hypertension |
Antineoplastic Agents Glaucoma Therapeutic Uses Growth Substances Eye Diseases Physiological Effects of Drugs |
Growth Inhibitors Angiogenesis Modulating Agents Bevacizumab Angiogenesis Inhibitors Pharmacologic Actions Ocular Hypertension |